Glycosylation inhibitors block the expression of LAV/HTLV-III (HIV) glycoproteins.
The glycosylation inhibitors 2-deoxy-D-glucose (2-dGlc) and, to a lesser extent, beta-hydroxynorvaline blocked the formation of syncytia in HIV (LAV/HTLV-III)-infected cells. Using monospecific polyclonal antibodies against recombinant envelope proteins gp110 and gp41 or monoclonal antibodies against env gp110, we could demonstrate a marked reduction in the immunoreactivity of these antigens in HIV-infected cells exposed to the glycosylation inhibitors. There was concomitant accumulation of core proteins p15 and p24, as shown by a solid phase radio-immunoassay, and a decreased oligosaccharide synthesis of env proteins, as monitored by the incorporation of [6-3H]GlcNAc. The reverse transcriptase was not affected by the compounds. Glycosylation inhibitors may be considered for the chemotherapy of AIDS or AIDS-related complex, or chemoprophylaxis of HIV-positive individuals.
D003837:Deoxy Sugars / Q000494:pharmacology*; D003847:Deoxyglucose / Q000494:pharmacology*; D006031:Glycosylation; D006678:HIV / Q000187:drug effects / Q000378:metabolism*; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D011863:Radioimmunoassay; D013912:Threonine / Q000031:analogs & derivatives* / Q000494:pharmacology; D014758:Viral Core Proteins / Q000378:metabolism; D014759:Viral Envelope Proteins / Q000276:immunology / Q000378:metabolism*; D014779:Virus Replication / Q000187:drug effects
D003837:Deoxy Sugars; D014758:Viral Core Proteins; D014759:Viral Envelope Proteins; C010994:3-hydroxynorvaline; D013912:Threonine; D003847:Deoxyglucose